

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

×



Memorial Sloan Kettering
Cancer Center

[Make an Appointment](#)

[Back](#)

[Press Releases](#)

[About MSK Cancer Treatment](#)

[Refer a Patient](#)

ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Equality, diversity & inclusion](#)

[Annual report](#)

[Give to MSK](#)

The current study included 750 patients over the age of 18 who were diagnosed with advanced kidney cancer and were previously untreated for the disease. Half were treated with a six-week cycle of sunitinib, and half were treated with a six-week cycle of IFN-alpha. The median progression-free survival for treatment with sunitinib was 11 months, compared with 5 months following treatment with IFN-alpha. In addition, 31 percent of the patients in the sunitinib arm of the study experienced substantial tumor shrinkage compared with 6 percent of the patients receiving the standard treatment.

Patients in the sunitinib group also reported significantly better health-related quality of life than those in the IFN-alpha group. Most toxicities observed with sunitinib treatment — such as hypertension, hand-foot syndrome, vomiting, and diarrhea — were ameliorated by dose interruption or modification.

Investigators from the following centers also contributed to the current study: Baylor Sammons Cancer Center/Texas Oncology PA, Dallas, TX; Klinika Onkologii Oddzial Chemioterapii, Poznan, Poland; Massachusetts General Hospital, Boston, MA; The Cleveland Clinic Foundation, Cleveland, OH; Hospital Pitie-Salpetriere, Paris, France; Hopital Europeen Georges-Pompidou, Paris, France; Centre Leon Berard, Lyon, France; Military Institute of Medicine, Warsaw, Poland; and City of Hope Comprehensive Cancer Center, Los Angeles, CA. The study was sponsored by Pfizer, Inc.

[Communication preferences](#)

[Cookie preferences](#)

[Legal disclaimer](#)

[Accessibility statement](#)

[Privacy policy](#)

[Price transparency](#)

[Public notices](#)

© 2024 Memorial Sloan Kettering Cancer Center